Online citations, reference lists, and bibliographies.
← Back to Search

Objective Assessment Of Tumour Response To Therapy Based On Tumour Growth Kinetics

E. Mehrara, Eva Forssell-Aronsson, P. Bernhardt
Published 2011 ·

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND: Current standards for assessment of tumour response to therapy (a) categorise therapeutic efficacy values, inappropriate for patient-specific and deterministic studies, (b) neglect the natural growth characteristics of tumours, (c) are based on tumour shrinkage, inappropriate for cytostatic therapies, and (d) do not accommodate integration of functional/biological means of therapeutic efficacy assessed with, for example, positron emission tomography or magnetic resonance imaging, with data from anatomical changes in tumour. METHODS: A quantity for tumour response was formulated assuming that an effective treatment may decrease the cell proliferation rate (cytostatic) and/or increase the cell loss rate (cytotoxic) of the tumour. Tumour response values were analysed for 11 non-Hodgkin’s lymphoma patients treated with I-labelled anti-B1 antibody and 12 prostate cancer patients treated with a nutritional supplement. RESULTS: Tumour response was found to be equal to the logarithm of the ratio of post-treatment tumour volume to the volume of corresponding untreated tumour. Neglecting the natural growth characteristics of tumours results in underestimation of treatment effectiveness based on currently used methods. The model also facilitates the integration of data from tumour volume changes, with data from functional imaging. CONCLUSION: Tumour response to therapy can be assessed with a continuous dimensionless quantity for both cytotoxic and cytostatic treatments. British Journal of Cancer (2011) 105, 682–686. doi:10.1038/bjc.2011.276 www.bjcancer.com Published online 26 July 2011 & 2011 Cancer Research UK
This paper references
10.1093/JNCI/DJJ086
Criticism of tumor response criteria raises trial design questions.
R. Twombly (2006)
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
P. Therasse (2000)
10.1148/radiol.10091760
Multiparametric imaging of tumor response to therapy.
A. Padhani (2010)
10.1038/nrc1883
Measuring response in a post-RECIST world: from black and white to shades of grey
L. Michaelis (2006)
10.1200/JCO.2006.07.3049
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Haesun Choi (2007)
10.1093/JNCI/DJM158
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
T. Karrison (2007)
10.1634/theoncologist.13-S2-14
Response assessment in clinical trials: implications for sarcoma clinical trial design.
C. Jaffe (2008)
Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.
T. Chenevert (1997)
The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas.
F. Blankenberg (1995)
An alternative model for the evaluation of antitumor activity.
P. Lavin (1981)
10.1016/0003-4975(95)00754-9
Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography.
F. Duhaylongsod (1995)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1097/00004728-200107000-00004
Mapping Therapeutic Response in a Patient with Malignant Glioma
S. Haney (2001)
10.1016/J.JHEP.2005.03.014
Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis.
A. Cucchetti (2005)
10.1038/nrc1650
Repopulation of cancer cells during therapy: an important cause of treatment failure
J. Kim (2005)
10.1002/pbc.20344
Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy
A. Barnacle (2006)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
10.1634/theoncologist.2007-0097
Application of PET/CT in the development of novel anticancer drugs.
D. Boss (2008)
10.1158/0008-5472.CAN-06-3822
Specific growth rate versus doubling time for quantitative characterization of tumor growth rate.
E. Mehrara (2007)
10.1002/PROS.10176
Using splines to detect changes in PSA doubling times
B. Guess (2003)
10.1634/theoncologist.2008-0075
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.
W. Stein (2008)
10.1093/ANNONC/MDM290
Response evaluation: beyond RECIST.
E. Eisenhauer (2007)
10.1200/JCO.2007.12.4487
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
H. Scher (2008)
10.1080/02841860802616736
Quantitative analysis of tumor growth rate and changes in tumor marker level: Specific growth rate versus doubling time
E. Mehrara (2009)
10.1016/j.crad.2008.01.012
Can FDG-PET be used to predict growth of stage I lung cancer?
M. Tann (2008)
10.1200/JCO.2006.09.2403
Revised response criteria for malignant lymphoma.
B. Cheson (2007)
10.1016/S1470-2045(00)00019-X
Repopulation of tumour cells between cycles of chemotherapy: a neglected factor.
A. Davis (2000)
Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
G. Sgouros (2003)
10.1016/S0959-8049(03)00073-X
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).
S. Stroobants (2003)
10.1093/JNCI/DJJ403
Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints.
R. Tuma (2006)
10.1016/J.EJCA.2007.10.010
How to assess anti-tumour efficacy by imaging techniques.
S. Gwyther (2008)



This paper is referenced by
Multiparametric MRI for evaluation of tumour treatment response
Mikael Montelius (2016)
10.1093/jjco/hyt139
CA125-related measures of tumor kinetics and outcome of patients with recurrent ovarian cancer receiving chemotherapy: a retrospective evaluation.
G. Colloca (2013)
10.1007/s12032-016-0817-x
CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience
G. Colloca (2016)
10.1007/s12094-015-1441-5
CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review
Giuseppe Antonio Colloca (2015)
10.1097/COC.0000000000000270
Tumor Growth Kinetics Before and After First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: A Prostate-specific Antigen-based Retrospective Analysis
Giuseppe Antonio Colloca (2018)
10.5772/39194
Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy
Hamilton Gerhard (2012)
10.5772/1888
Cytokeratins - Tools in Oncology
G. Hamilton (2012)
10.4317/medoral.23003
Radiographic estimation of the growth rate of initially underdiagnosed ameloblastomas
B. A. Mariz (2019)
10.5772/53179
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate
G. Tisman (2013)
10.1186/1742-4682-11-21
Analysis of inter-patient variations in tumour growth rate
E. Mehrara (2014)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.1016/j.apsb.2018.07.012
Tat-functionalized Ag-Fe3O4 nano-composites as tissue-penetrating vehicles for tumor magnetic targeting and drug delivery
Ergang Liu (2018)
10.1093/annonc/mds535
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Z. Labby (2013)
10.1186/s41241-018-0062-z
Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume
E. Mehrara (2018)
10.1016/j.lungcan.2013.12.013
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
M. Macerelli (2014)
10.1371/journal.pone.0117241
Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis
Michael P. Chae (2015)
10.1016/j.lungcan.2015.07.011
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
S. Armato (2015)
10.1016/j.eururo.2013.08.010
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
C. Ferté (2014)
10.1097/JTO.0b013e31828354c8
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma
Z. Labby (2013)
Semantic Scholar Logo Some data provided by SemanticScholar